Immune checkpoint inhibitors (ICIs), including anti-PD-1 antibodies (nivolumab and pembrolizumab) and anti-PD-L1 antibodies (atezolizumab), have revolutionized cancer immunotherapy in NSCLC, melanoma, and renal cell carcinoma [158,159,160]. The gene discussed is CD274; the disease is cancer.